Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ocrevus

- PMLiVE

Roche and Novartis part ways with share purchase

Novartis is to sell its one-third stake in Roche for more than $20bn, paving the way for potential acquisitions

- PMLiVE

New data shows Roche’s Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses

Enspryng is the first and only NMOSD treatment administered subcutaneously every four weeks

- PMLiVE

Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS

The data presented at ECTRIMS 2021 reinforces the efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis

Sanofi reception

Sanofi’s tolebrutinib demonstrates favourable one-year tolerability in patients with relapsing forms of multiple sclerosis

New long-term data presented at ECTRIMS 2021 reinforces promising safety and efficacy profile

Biogen Idec building

Data shows patients treated with Biogen’s MS therapies mount an effective antibody response to COVID-19 vaccination

New MS PATHS data was presented at ECTRIMS 2021

Roche Basel Switzerland

New data for Tecentriq in early-stage lung cancer

Roche’s PD-L1 blocker reduced the risk of disease recurrence and death for patients with stage 2-3a non-small cell lung cancer following surgery

Biogen Idec building

Biogen’s Vumerity recommended by CHMP in MS

A thumbs up for Vumerity in the EU could ease the way for Biogen’s follow-up to Tecfidera in multiple sclerosis

Roche Basel Switzerland

Roche expands infectious disease test portfolio

PCR test specialist TIB Molbiol will join Roche to bolster its molecular diagnostics solutions for infectious diseases

Roche Basel Switzerland

Roche expands infectious disease test portfolio

PCR test specialist TIB Molbiol will join Roche to bolster its molecular diagnostics solutions for infectious diseases

Roche Basel Switzerland

Roche bets on T-cell therapies with Adaptimmune deal

Genentech signs deal for five ‘off the shelf’ T-cell therapies and a personalised cell therapy platform in a deal potentially worth more than $3bn

Roche Basel Switzerland

Tecentriq withdrawn in hard-to-treat breast cancer in US

A post-marketing study failed to show benefit for patients with triple-negative breast cancer taking Tecentriq and chemotherapy

Roche Basel Switzerland

FDA approval for Roche diagnostic solid tumour test

Test will identify which patients could benefit from GSK immunotherapy.

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links